Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07435090
PHASE2/PHASE3

Efficacy and Safety of Rimegepant for Acute Dizziness

Sponsor: Shi Tianming

View on ClinicalTrials.gov

Summary

This study aims to explore the efficacy and safety of rimegepant for acute dizziness, including vestibular migraine (VM) and benign recurrent vertigo (BRV), through a multicenter, randomized controlled clinical trial. This study addresses the urgent clinical need for effective therapies for acute dizziness. Additionally, we will dynamically observe the changes in calcitonin gene-related peptide (CGRP) levels before and after treatment and explore the predictive value of CGRP levels for treatment efficacy and the prognosis of recurrence in patients. This study aims to provide a scientific basis to improve clinical management strategies for acute dizziness.

Official title: A Multicenter Randomized Controlled Trial on the Efficacy and Safety of Rimegepant in the Treatment of Acute Dizziness

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

370

Start Date

2026-03-20

Completion Date

2028-06-30

Last Updated

2026-02-27

Healthy Volunteers

No

Conditions

Interventions

DRUG

Rimegepant 75mg Orally Disintegrating Tablets (ODT)

A single dose of Rimegepant orally disintegrating tablets (75 mg) combined with betahistine mesylate (12 mg) administered orally.

DRUG

Betahistine Mesylate tablet

A single dose of betahistine mesylate (12 mg) administered orally.